1.42
+0.0198(+1.41%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.42 |
| Day High | 1.44 |
| Day Low | 1.41 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.91 |
| Volume | 20,718 |
| Average Volume | 146,846 |
| Market Cap | 84.11M |
| PE | -3.16 |
| EPS | -0.45 |
| Moving Average 50 Days | 1.35 |
| Moving Average 200 Days | 1.21 |
| Change | 0.02 |
If you invested $1000 in Vivani Medical, Inc. (VANI) 10 years ago, it would be worth $9.98 as of September 30, 2025 at a share price of $1.42. Whereas If you bought $1000 worth of Vivani Medical, Inc. (VANI) shares 5 years ago, it would be worth $549.03 as of September 30, 2025 at a share price of $1.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
GlobeNewswire Inc.
Sep 24, 2025 1:15 PM GMT
ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will pres
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
GlobeNewswire Inc.
Sep 17, 2025 12:30 PM GMT
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s new Orion® art
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
GlobeNewswire Inc.
Sep 04, 2025 12:30 PM GMT
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study